Ocugen (NASDAQ:OCGN - Get Free Report) is set to announce its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Ocugen (NASDAQ:OCGN - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The firm had revenue of $1.14 million during the quarter. During the same quarter in the prior year, the company earned ($0.10) EPS. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Ocugen Stock Up 4.2 %
Shares of NASDAQ:OCGN traded up $0.04 during mid-day trading on Friday, reaching $0.95. The stock had a trading volume of 2,374,852 shares, compared to its average volume of 6,192,490. The business's 50 day moving average price is $1.07 and its 200 day moving average price is $1.37. Ocugen has a 1 year low of $0.35 and a 1 year high of $2.11. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.04 and a quick ratio of 1.04.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on OCGN shares. Maxim Group started coverage on shares of Ocugen in a research report on Tuesday, October 15th. They issued a "buy" rating and a $4.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $7.00 price target on shares of Ocugen in a research report on Wednesday, October 23rd.
Get Our Latest Stock Analysis on Ocugen
Ocugen Company Profile
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Further Reading
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
